$Remitting&ndash;relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab$

Remitting&ndash;relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab

Athanasia Mouzaki1, Maria Koutsokera2, Zoe Dervilli1, Maria Rodi1, Dimitra Kalavrizioti1,3, Nikolaos Dimisianos2, Ioannis Matsoukas3, Panagiotis Papathanasopoulos21Division of Hematology, Department of Internal Medicine, 2Neurology Clinic, Medical School and University Hospital, 3Department of Chemi...

Full description

Bibliographic Details
Main Authors:	Athanasia Mouzaki, Maria Koutsokera, Zoe Dervilli, et al
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-09-01
Series:	International Journal of General Medicine
Online Access:	http://www.dovepress.com/remittingndashrelapsing-multiple-sclerosis-patient-refractory-to-conve-a5356

Similar Items

Natalizumab for relapsing-remitting multiple sclerosis
by: A. Horga, et al.
Published: (2011-01-01)

Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis
by: Fabricio Gonz&aacute;lez-Andrade, et al.
Published: (2010-07-01)

Advances in the treatment of relapsing&ndash;remitting multiple sclerosis &ndash; critical appraisal of fingolimod
by: Gasperini C, et al.
Published: (2013-03-01)

Alemtuzumab: evidence for its potential in relapsing&ndash;remitting multiple sclerosis
by: Brown JWL, et al.
Published: (2013-03-01)

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
by: Gatzonis Stylianos, et al.
Published: (2009-08-01)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
by: Mehdi Rezaee, et al.
Published: (2022-01-01)

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
by: Diego Cadavid, et al.
Published: (2013-01-01)

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
by: Planas R, et al.
Published: (2014-04-01)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
by: Martha Rocio Hernández-Preciado, et al.
Published: (2022-06-01)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
by: Mansour A. Alharbi, et al.
Published: (2023-05-01)

Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
by: Takahiko Saida, et al.
Published: (2023-08-01)

Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells
by: Radu Tanasescu, et al.
Published: (2023-09-01)

Cost minimisation analysis of fingolimod vs. natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis
by: C. Crespo, et al.
Published: (2014-05-01)

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
by: Anna Jamroz-Wiśniewska, et al.
Published: (2021-04-01)

A COMPARATIVE ANALYSIS OF EFFICACY OF INTERFERON BETA 1-B AND NATALIZUMAB TREATMENT IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: T. I. Yakushina, et al.
Published: (2016-07-01)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
by: Oreja-Guevara Celia, et al.
Published: (2012-09-01)

Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis
by: King Man Wan, et al.
Published: (2019-01-01)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
by: Bayas A, et al.
Published: (2015-02-01)

Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing&ndash;remitting multiple sclerosis?
by: Mezei Z, et al.
Published: (2012-10-01)

The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) Study
by: B Polistena, et al.
Published: (2019-06-01)

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter
by: A. Pato Pato, et al.
Published: (2021-06-01)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
by: Guarnera C, et al.
Published: (2017-07-01)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
by: Reardon J, et al.
Published: (2013-10-01)

Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis
by: Jai Perumal, et al.
Published: (2023-03-01)

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE
by: Jai Perumal, et al.
Published: (2019-06-01)

Interferons in relapsing remitting multiple sclerosis.
by: Goodin, D
Published: (2003)

Comparison Of The Expression Of MiR-326 Between Interferon Beta Responders And Non-Responders In Relapsing-Remitting Multiple Sclerosis
by: Mahtab Fattahi, et al.
Published: (2020-04-01)

Real-world evidence and patient preference for subcutaneous intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis – initial results from the observational SISTER study
by: Ralf Gold, et al.
Published: (2024-04-01)

The effectiveness of Natalizumab on MRI outcome measures in patients with relapsing multiple sclerosis
by: Dalton, C, et al.
Published: (2003)

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
by: Ruggieri S, et al.
Published: (2014-03-01)

Direct costs of relapses in patients with relapsing-remitting multiple sclerosis
by: V. Casado, et al.
Published: (2021-07-01)

Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis
by: Cifelli, A, et al.
Published: (2003)

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
by: Wylezinska, M, et al.
Published: (2003)

Postural Control in Relapsing-Remitting Multiple Sclerosis
by: Flavia Salvaterra Cusin, et al.
Published: (2022-10-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
by: Radu Tanasescu, et al.
Published: (2014-04-01)

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01)

Cognitive impairment in relapsing remitting Multiple Sclerosis
by: Saška Roškar
Published: (2003-06-01)

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
by: Marina Boziki, et al.
Published: (2021-08-01)

Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report
by: Constantin Gabriela, et al.
Published: (2010-09-01)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
by: Filippini, G, et al.
Published: (2003)